Results 21 to 30 of about 1,103 (154)

An investigator-blind randomized controlled trial comparing effectiveness, safety of levocetirizine and bepotastine in chronic urticaria [PDF]

Indian Journal of Dermatology, 2021
Introduction: Chronic urticaria is common and distressing dermatosis where the search for newer agents with improved effectiveness and tolerability profile is a felt need.
Amrita Sil, Sufiur Rahaman, Nasiruddin Mondal, Sk Shahriar Ahmed, Dhiman Tarafdar, Aparesh Chandra Patra, Sudipta Roy, Nilay Kanti Das   +7 more
doaj   +2 more sources

Comparative inhibitory effects of bepotastine and diphenhydramine on rituximab-induced infusion reactions. [PDF]

Int J Hematol
Purpose Infusion-related reaction (IRR) is a common adverse event induced by rituximab. Although first-generation histamine 1 receptor antagonists (H1RAs) are commonly used to prevent IRR, evidence on IRR suppression by the second-generation H1RA ...
Hori T, Yamamoto K, Nakagawa T, Nakagawa R, Okayama M, Sudou T, Hamasaki M, Yasuda M, Kobayashi S, Nakamura F, Yagi H, Kitahiro Y, Ikushima S, Yano I.   +13 more
europepmc   +2 more sources

Dermatopathological Findings of an Erythema Multiforme‐Like Drug Eruption During Enfortumab Vedotin Plus Pembrolizumab Therapy for Metastatic Urothelial Carcinoma: A Case Report [PDF]

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT The combination therapy of enfortumab vedotin and pembrolizumab (EV+Pem) is effective for metastatic urothelial carcinoma. However, the dermatopathological findings for treatment‐related adverse events, particularly skin disorders, often remain unclear.
Ryunosuke Murofushi, Yoichiro Kato, Takashi Seo, Kazuhiro Iwasaki, Maki Goto, Nobuhiro Monma, Shigekatsu Maekawa, Wataru Obara   +7 more
wiley   +2 more sources

Comparison of cytotoxicities and anti-allergic effects of topical ocular dual-action anti-allergic agents [PDF]

BMC Ophthalmology, 2019
Background To investigate the cytotoxicities of the topical ocular dual-action anti-allergic agents (alcaftadine 0.25%, bepotastine besilate 1.5%, and olopatadine HCL 0.1%) on human corneal epithelial cells (HCECs) and their anti-allergic effects on ...
Sung Il Kim, Choul Yong Park, Gladys Fordjuor, Jong Heon Lee, Jong Soo Lee, Ji Eun Lee   +5 more
doaj   +2 more sources

New drugs: Asenapine, iloperidone, and bepotastine besilate

Journal of the American Pharmacists Association, 2010
Antipsychotic agents Asenapine (Saphris—Schering) and iloperidone (Fanapt—Vanda) are new atypical antipsychotic agents that join an already large class of these drugs that includes aripiprazole (Abilify), clozapine (e.g., Clozaril), olanzapine (Zyprexa), quetiapine (Seroquel), ziprasidone (Geodon), and risperidone (e.g., Risperdal) and its active ...
Cheryl A. Abbas, Daniel A. Hussar
core   +3 more sources

Comparison of efficacy of topical bepotastine besilate and alcaftadine in patients with vernal keratoconjunctivitis

Indian Journal of Clinical and Experimental Ophthalmology
To compare efficacy of bepotastine besilate (1.5%) versus alcaftadine (0.25%) in patients with vernal keratoconjunctivitis.This comparative, randomized, single-blind and prospective study was conducted on 100 patients diagnosed with VKC, who were ...
Neha Yadav, S. Sachdeva, Manisha Rathi, Sonia Chhabra, Shreay Vashisth, Dinkar Yadav   +5 more
semanticscholar   +2 more sources

Development and Validation of a Multiplex Flow Cytometry‐Based PBMC Assay for Immunomodulator Screening [PDF]

Journal of Immunology Research, Volume 2026, Issue 1, 2026.
The identification of novel compounds capable of stimulating or suppressing immune responses is critical for advancing immunotherapy and improving our understanding of immune regulation. However, traditional screening approaches are often limited by low throughput, poor physiological relevance, and insufficient resolution to detect subtle ...
Regine Brox, Holger Hackstein, Poorani Gurumallesh Prabu   +2 more
wiley   +2 more sources

Concentrations of H1‐Receptor Antagonist in the Human Nasal Mucosa [PDF]

International Journal of Otolaryngology, Volume 2009, Issue 1, 2009., 2009
Aims. To measure blood and tissue concentrations of the H1‐receptor antagonist, bepotastine besilate (BB). Methods. Participants included 14 men and six women, whose age ranged from 13 to 76 years, with chronic rhinosinusitis, who underwent endoscopic sinus surgery at our university hospital.
Kenji Takasaki, Kaori Enatsu, Hidetaka Kumagami, Haruo Takahashi, Fuad Baroody   +4 more
wiley   +2 more sources

A study on the use of topical bepotastine besilate ophthalmic solution (BBOS) 1.5% in the treatment of allergic conjunctivitis

Indian Journal of Clinical and Experimental Ophthalmology, 2019
The study was conducted to ascertain the efficacy and safety of topical bepotastine besilate solution (BBOS) 1.5% in controlling allergic conjunctivitis. The study design was randomized and out-patient department (OPD) based.
Nageshwar Sharma, Jayshree Kedia
semanticscholar   +3 more sources

Model of Chronic Itch in Aged Mice: Beneficial Effects of Drugs Affecting Descending Modulatory Systems. [PDF]

Acta Derm Venereol
Pruritus in the elderly, particularly those cases without skin dryness or other identifiable causes, makes treatment challenging due to the lack of evidence regarding the therapeutic effects of antipruritics. This study proposes an age-related alloknesis
Kojima G, Komiya E, Honda K, Kaneko T, Suga Y, Tominaga M, Takamori K.   +6 more
europepmc   +2 more sources